A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Conditions: Clear Cell Renal Cell Carcinoma; Cervical Carcinoma; Esophageal Carcinoma; Pancreatic Adenocarcinoma; Malignant Pleural Mesothelioma Intervention: Biological: CTX131 Sponsor: CRISPR Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2023 Category: Research Source Type: clinical trials